Index Entries

Kristen W. Cohen, Susanne L. Linderman, Zoe Moodie, Julie Czartoski, Lilin Lai, Grace Mantus, Carson Norwood, Lindsay E. Nyhoff, Venkata Viswanadh Edara, Katharine Floyd, Stephen C. De Rosa, Hasan Ahmed, Rachael Whaley, Shivan N. Patel, Brittany Prigmore, Maria P. Lemos, Carl W. Davis, Sarah Furth, James B. O’Keefe, Mohini P. Gharpure, Sivaram Gunisetty, Kathy Stephens, Rustom Antia, Veronika I. Zarnitsyna, David S. Stephens, Srilatha Edupuganti, Nadine Rouphael, Evan J. Anderson, Aneesh K. Mehta, Jens Wrammert, Mehul S. Suthar, Rafi Ahmed, M. Juliana McElrath
July 14, 2021
Cell Reports Medicine
Fred Hutchinson Cancer Research Center (Washington)

Summary: Ending the COVID-19 pandemic will require long-lived immunity to SARS-CoV-2. Here, we evaluate 254 COVID-19 patients longitudinally up to eight months and find durable broad-based immune responses… Taken together, these results suggest that broad and effective immunity may persist long-term in recovered COVID-19 patients…

Discussion: … Our findings show that most COVID-19 patients induce a wide-ranging immune defense against SARS-CoV-2 infection, encompassing antibodies and memory B cells recognizing both the RBD and other regions of the spike, broadly-specific and polyfunctional CD4+ T cells, and polyfunctional CD8+ T cells. The immune response to natural infection is likely to provide some degree of protective immunity even against SARS-CoV-2 variants because the CD4+ and CD8+ T cell epitopes will likely be conserved.”

document
natural immunity